23,338,039
Vote Records
27,979
Companies
11,817
Funds
4,051
Managers

Home › Companies › Aclaris Therapeutics, Inc. › 2025-2026

Aclaris Therapeutics, Inc. 2025-2026 Proxy Voting Records

Download data (CSV): ballot items · votes by manager · column guide.

Compiled from SEC Form N-PX filings and Aclaris Therapeutics, Inc.’s Form 8-K, filed June 4, 2026 (Item 5.07 on EDGAR). Page generated November 20, 2026.

  • 4Ballot items
  • 140Asset managers, any item
  • 630Fund votes
  • June 4, 2026Meeting date

Results at a glance

Meeting of June 4, 2026: 4 items on Aclaris Therapeutics, Inc.’s Form 8-K, filed June 4, 2026: 2 approved · 2 passed (calculated).

Dissent

Notable dissent: 1 director (10.8% against).

Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided

Proxy season: 2023-2024 2024-2025 2025-2026

Activist investors: Ra Capital Management, L.P. (13F, 8.0%, as of September 30, 2026) · BML Capital (13F, 6.9%, as of September 30, 2026)

Explore Aclaris Therapeutics, Inc. in the interactive database Compare manager voting policies

Official 2025-2026 meeting results reported by Aclaris Therapeutics, Inc.

These tallies are Aclaris Therapeutics, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 4, 2026 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

Aclaris Therapeutics, Inc. — official shareholder meeting results, meeting held June 4, 2026
Ballot itemForAgainst AbstainWithheldBroker non-votesSupport (of votes cast)Reported outcomeVoting standard
Elect Director: Anand Mehra, M.D. 83,063,569---- 10,075,62419,360,478 89%Passed (calculated)—
Elect Director: Maxine Gowen, Ph.D. 84,209,108---- 8,930,08519,360,478 90%Passed (calculated)—
2. The compensation of the Company's named executive officers, as disclosed in the Proxy Statement 83,370,1249,734,69134,378 --19,360,478 90%Approved—
3. The selection by the Audit Committee of the Board of Directors of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026 112,322,811159,71417,146 ---- 99.9%Approved—

Source: Aclaris Therapeutics, Inc., Form 8-K, filed with the SEC on June 4, 2026 — read the filing on EDGAR.

How asset managers voted at the Aclaris Therapeutics, Inc. 2025-2026 meeting

140 asset managers disclosed a vote on at least one Aclaris Therapeutics, Inc. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report.

Elect Director: Anand Mehra, M.D.

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 5 wordings of this item as funds reported it.

89% Majority: yes · of votes cast

FOR 89%
FOR: 83,063,569WITHHELD: 10,075,624
Details: description as filed, official tally, votes by 48 asset managers

Description as filed by funds: Election of Directors: Anand Mehra, M.D.

Aclaris Therapeutics, Inc.’s own tally for this item (“Elect Director: Anand Mehra, M.D.”): 83,063,569 for, 10,075,624 withheld, per its Form 8-K filed June 4, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 89% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 48 asset managers below reported 13,870,850 for, 1,152,447 withheld, 47,632 abstained.

FOR
FOR: 13,870,850ABSTAIN: 47,632WITHHOLD: 1,152,447
Largest asset managers voting on “Election of Directors: Anand Mehra, M.D.” at Aclaris Therapeutics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard5,922,5770 167,626For
BlackRock4,271,2360 00For
Fidelity2,080,1530 0144,393Mixed
JPMorgan280,1730 00For
Charles Schwab260,9630 00For
BRIDGEWAY FUNDS INC00 0223,739Withhold
Equitable151,2440 07,600For
QUANTITATIVE MASTER SERIES LLC157,2630 00For
Russell Investments140,9370 00For
Dimensional00 0140,259Withhold
Goldman Sachs119,8750 00For
American Century00 0118,702Withhold
Brighthouse75,2680 029,643Mixed
AIG/SunAmerica00 0102,584Withhold
ALPS ETF Trust00 098,175Withhold
TIAA00 090,480Withhold
Invesco80,5590 00For
Lincoln Financial67,0000 00For
Pacific Life35,7160 019,779Mixed
Global X43,4540 00For
Bridge Builder Trust42,3530 00For
Northern Trust00 042,210Withhold
AQR00 035,656Withhold
State Street33,6330 00For
FORUM FUNDS II28,4310 00For

Showing the 25 largest of 48 asset managers. All 48 are in the interactive database (link above).

Elect Director: Maxine Gowen, Ph.D.

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 5 wordings of this item as funds reported it.

90% Majority: yes · of votes cast

FOR 90%
FOR: 84,209,108WITHHELD: 8,930,085
Details: description as filed, official tally, votes by 48 asset managers

Description as filed by funds: Election of Directors: Maxine Gowen, Ph.D.

Aclaris Therapeutics, Inc.’s own tally for this item (“Elect Director: Maxine Gowen, Ph.D.”): 84,209,108 for, 8,930,085 withheld, per its Form 8-K filed June 4, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 90% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 48 asset managers below reported 13,931,312 for, 1,091,986 withheld, 47,631 abstained.

FOR
FOR: 13,931,312ABSTAIN: 47,631WITHHOLD: 1,091,986
Largest asset managers voting on “Election of Directors: Maxine Gowen, Ph.D.” at Aclaris Therapeutics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard5,922,5780 157,626For
BlackRock4,271,2360 00For
Fidelity2,080,1530 0144,393Mixed
JPMorgan280,1730 00For
Charles Schwab260,9630 00For
BRIDGEWAY FUNDS INC00 0223,739Withhold
Equitable158,8440 00For
QUANTITATIVE MASTER SERIES LLC157,2630 00For
Russell Investments140,9370 00For
Dimensional00 0140,259Withhold
Goldman Sachs119,8750 00For
American Century00 0118,702Withhold
Brighthouse75,2680 029,643Mixed
AIG/SunAmerica00 0102,584Withhold
ALPS ETF Trust00 098,175Withhold
TIAA00 090,480Withhold
Invesco80,5590 00For
Lincoln Financial67,0000 00For
Pacific Life35,7160 019,779Mixed
Global X43,4540 00For
Bridge Builder Trust42,3530 00For
Northern Trust42,2100 00For
AQR00 035,656Withhold
State Street33,6330 00For
FORUM FUNDS II28,4310 00For

Showing the 25 largest of 48 asset managers. All 48 are in the interactive database (link above).

The compensation of the Company's named executive officers, as disclosed in the Proxy Statement

Official resultFund totals may overlapSECTION 14A SAY-ON-PAY VOTESReported outcome: Approved

Combines 7 wordings of this item as funds reported it.

90% Approved · of votes cast

FOR 90%
FOR: 83,370,124AGAINST: 9,734,691

Prior year: 76.6% for (June 5, 2025 meeting) ▲ 13.0 pts

Details: description as filed, official tally, votes by 140 asset managers

Description as filed by funds: To approve, on an advisory basis, the compensation of our named executive officers, as disclosed in the proxy statement accompanying the proxy card.

Aclaris Therapeutics, Inc.’s own tally for this item (“2. The compensation of the Company's named executive officers, as disclosed in the Proxy Statement”): 83,370,124 for, 9,734,691 against — passed, per its Form 8-K filed June 4, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal No. 2 : The stockholders approved, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the Proxy Statement.”
Support: 90% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 48 asset managers voting on “To approve, on an advisory basis, the compensation of our named executive officers, as disclosed in the proxy ” at Aclaris Therapeutics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard5,926,5503,669 00For
BlackRock4,271,2360 00For
Fidelity2,080,153144,393 00Mixed
JPMorgan0280,173 00Against
Charles Schwab260,9630 00For
BRIDGEWAY FUNDS INC0223,739 00Against
Equitable151,2447,600 00For
QUANTITATIVE MASTER SERIES LLC157,2630 00For
Russell Investments140,9370 00For
Dimensional0140,259 00Against
Goldman Sachs119,8750 00For
American Century118,7020 00For
Brighthouse0104,911 00Against
AIG/SunAmerica0102,584 00Against
ALPS ETF Trust098,175 00Against
TIAA90,4800 00For
Invesco080,559 00Against
Lincoln Financial67,0000 00For
Pacific Life35,71619,779 00Mixed
Global X43,4540 00For
Bridge Builder Trust42,3530 00For
Northern Trust42,2100 00For
AQR035,656 00Against
State Street33,6330 00For
FORUM FUNDS II28,4310 00For

Fund voting reports, all 48 managers: 13,690,780 for, 1,370,810 against, 9,339 abstained. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 109 asset managers voting on “To approve, on an advisory basis, the compensation of our named executive officers, as disclosed in the proxy ” at Aclaris Therapeutics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Deep Track Capital, LP9,345,0000 00For
RA CAPITAL MANAGEMENT, L.P.8,316,2390 00For
Vivo Capital, LLC6,666,6660 00For
Frazier Life Sciences Management, L.P.4,925,3740 00For
Rock Springs Capital Management LP4,472,6500 00For
Decheng Capital LLC4,041,7360 00For
ADAGE CAPITAL PARTNERS GP, L.L.C.03,871,000 00Against
BlackRock2,675,17056,214 00For
GEODE CAPITAL MANAGEMENT, LLC2,426,0940 00For
State Street1,886,19325,061 00For
Kalehua Capital Management LLC1,832,3650 00For
Woodline Partners LP1,271,3290 00For
ACADIAN ASSET MANAGEMENT LLC01,035,652 00Against
Aldebaran Capital, LLC947,5510 00For
Citadel800,3670 00For
Vanguard697,6524,123 00For
Northern Trust642,46130,689 00For
BALYASNY ASSET MANAGEMENT L.P.626,9850 00For
BRAIDWELL LP587,3990 00For
Renaissance0439,517 00Against
Aisling Capital Management LP434,4550 00For
T. Rowe Price0407,874 00Against
MPM BioImpact LLC391,9180 00For
SUPERSTRING CAPITAL MANAGEMENT LP366,4900 00For
MARSHALL WACE, LLP333,5310 00For

Institutional-manager reports, all 109 managers: 55,447,071 for, 8,620,550 against, 351 not voted. Showing the 25 largest; every one is in the interactive database (link above).

The selection by the Audit Committee of the Board of Directors of PricewaterhouseCoopers LLP as the Company's…

Official resultAUDIT-RELATEDReported outcome: Approved

Combines 3 wordings of this item as funds reported it.

99.9% Approved · of votes cast

FOR 99.9%
FOR: 112,322,811AGAINST: 159,714

Prior year: 99.6% for (June 5, 2025 meeting) ▲ 0.3 pts

Details: description as filed, official tally, votes by 48 asset managers

Description as filed by funds: To ratify the selection by the Audit Committee of the Board of Directors of PricewaterhouseCoopers LLP as the independent registered public accounting firm of Aclaris Therapeutics, Inc. for its fiscal year ending December 31, 2026.

Aclaris Therapeutics, Inc.’s own tally for this item (“3. The selection by the Audit Committee of the Board of Directors of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026”): 112,322,811 for, 159,714 against — passed, per its Form 8-K filed June 4, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal No. 3: The stockholders ratified the selection by the Audit Committee of the Board of Directors of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026.”
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 48 asset managers below reported 15,061,590 for, 9,339 abstained.

FOR
FOR: 15,061,590ABSTAIN: 9,339
Largest asset managers voting on “To ratify the selection by the Audit Committee of the Board of Directors of PricewaterhouseCoopers LLP as the ” at Aclaris Therapeutics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard5,930,2190 00For
BlackRock4,271,2360 00For
Fidelity2,224,5460 00For
JPMorgan280,1730 00For
Charles Schwab260,9630 00For
BRIDGEWAY FUNDS INC223,7390 00For
Equitable158,8440 00For
QUANTITATIVE MASTER SERIES LLC157,2630 00For
Russell Investments140,9370 00For
Dimensional140,2590 00For
Goldman Sachs119,8750 00For
American Century118,7020 00For
Brighthouse104,9110 00For
AIG/SunAmerica102,5840 00For
ALPS ETF Trust98,1750 00For
TIAA90,4800 00For
Invesco80,5590 00For
Lincoln Financial67,0000 00For
Pacific Life55,4950 00For
Global X43,4540 00For
Bridge Builder Trust42,3530 00For
Northern Trust42,2100 00For
AQR35,6560 00For
State Street33,6330 00For
FORUM FUNDS II28,4310 00For

Showing the 25 largest of 48 asset managers. All 48 are in the interactive database (link above).

Largest Aclaris Therapeutics, Inc. shareholders voting in 2025-2026

Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 139,663,680 shares outstanding at the time of that meeting.

Fund voting reports: top Aclaris Therapeutics, Inc. shareholders by shares voted on “To approve, on an advisory basis, the compensation of our named executive officers, as…”, 2025-2026
#Asset manager % of shares outstanding
1Vanguard 4.25%
2BlackRock 3.06%
3Fidelity 1.59%
4JPMorgan 0.20%
5Charles Schwab 0.19%
6BRIDGEWAY FUNDS INC 0.16%
7Equitable 0.11%
8QUANTITATIVE MASTER SERIES LLC 0.11%
9Russell Investments 0.10%
10Dimensional 0.10%
Institutional-manager reports: top Aclaris Therapeutics, Inc. shareholders by shares voted on “To approve, on an advisory basis, the compensation of our named executive officers, as…”, 2025-2026
#Asset manager % of shares outstanding
1Deep Track Capital, LP 6.69%
2RA CAPITAL MANAGEMENT, L.P. 5.95%
3Vivo Capital, LLC 4.77%
4Frazier Life Sciences Management, L.P. 3.53%
5Rock Springs Capital Management LP 3.20%
6Decheng Capital LLC 2.89%
7ADAGE CAPITAL PARTNERS GP, L.L.C. 2.77%
8BlackRock 1.96%
9GEODE CAPITAL MANAGEMENT, LLC 1.74%
10State Street 1.37%

Reported Aclaris Therapeutics, Inc. holdings and ownership

As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.

Aclaris Therapeutics, Inc. holdings and ownership disclosed for the 2025-2026 proxy season, with each row’s source and date
HolderShares % outstandingSource, as of
BML Investment Partners, L.P.13,950,000 9.99%Schedule 13G, filed April 27, 2026
Biosion, Inc.11,281,950 8.08%Schedule 13G, filed January 9, 2026
Frazier Life Sciences Public Fund, L.P.7,879,943 5.64%Schedule 13G, filed September 21, 2026
BlackRock7,407,065 5.30%Form 13F, quarter ended March 31, 2026
Vanguard Group6,502,080 4.66%Form 13F, quarter ended March 31, 2026
Vivo Opportunity Fund Holdings, L.P.5,966,370 4.27%Schedule 13G, filed May 12, 2026
Morgan Stanley3,415,390 2.45%Form 13F, quarter ended March 31, 2026
Citadel Advisors2,818,019 2.02%Form 13F, quarter ended March 31, 2026
Geode Capital2,423,691 1.74%Form 13F, quarter ended March 31, 2026
State Street2,008,746 1.44%Form 13F, quarter ended March 31, 2026

Percentages above are of 139,663,680 shares outstanding, as reported by Aclaris Therapeutics, Inc. on its Form 10-Q dated April 30, 2026 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.

About this meeting

At Aclaris Therapeutics, Inc.'s shareholder meeting held June 4, 2026, in the 2025-2026 proxy season, 140 asset managers reported votes on at least one of its 4 ballot items in their SEC Form N-PX filings, covering 630 separate fund positions. On the most widely held item on that ballot — To approve, on an advisory basis, the compensation of our named executive officers, as… — Aclaris Therapeutics, Inc.'s filing reports the proposal as approved, with 90% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: Aclaris Therapeutics, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 4, 2026.

Related

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Aclaris Therapeutics, Inc.’s 10-Q dated April 30, 2026. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.

Aclaris Therapeutics, Inc. proxy season coverage: 2023-2024 · 2024-2025 · 2025-2026 (this page).

Cite this page

Proxy Votes Now, “Aclaris Therapeutics (ACRS) 2026 Annual Meeting: Vote Results”, https://proxyvotesnow.com/company/aclaris-therapeutics-inc/2026 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.